Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men

CJ Hukshorn, WHM Saris… - The Journal of …, 2000 - academic.oup.com
CJ Hukshorn, WHM Saris, MS Westerterp-Plantenga, AR Farid, FJ Smith, LA Campfield
The Journal of Clinical Endocrinology & Metabolism, 2000academic.oup.com
To assess the biological activity and tolerability of pegylated recombinant native human
leptin (PEG-OB), 30 obese men (mean body mass index, 33.9 kg/m2) were randomized to a
double-blind treatment with weekly sc injections of 20 mg PEG-OB or placebo for 12 weeks,
in addition to a hypocaloric diet (deficit, 2 MJ/day). Body composition, energy expenditure,
and metabolic parameters were measured before and after treatment. PEG-OB was
generally well tolerated based on adverse event reports, lab values, and vital signs. Weekly …
To assess the biological activity and tolerability of pegylated recombinant native human leptin (PEG-OB), 30 obese men (mean body mass index, 33.9 kg/m2) were randomized to a double-blind treatment with weekly sc injections of 20 mg PEG-OB or placebo for 12 weeks, in addition to a hypocaloric diet (deficit, 2 MJ/day). Body composition, energy expenditure, and metabolic parameters were measured before and after treatment. PEG-OB was generally well tolerated based on adverse event reports, lab values, and vital signs. Weekly sc PEG-OB led to sustained serum concentrations of PEG-OB and leptin throughout treatment. No significant differences in the delta or percent weight loss, percent body fat, sleeping metabolic rate, or respiratory quotient were observed between the PEG-OB and placebo groups. Percent change in serum triglycerides from baseline was significantly correlated with body weight loss in the PEG-OB group, but not in the placebo group. Although larger reductions in serum triglycerides were observed in the PEG-OB group compared with the placebo group, these differences were not statistically significant. We concluded that weekly injection of PEG-OB leads to sustained serum concentration of PEG-OB and leptin throughout the 12-week treatment period and is generally well tolerated. The trends observed in serum triglycerides suggest that a weekly 20-mg sc treatment with PEG-OB may have biological effects in obese men.
Oxford University Press